Half-Year Review of Inventiva’s Liquidity Contract with Kepler
Cheuvreux
Daix (France), Long Island City (New York),
January 14, 2022 – Inventiva (Euronext Paris and Nasdaq:
IVA), a clinical-stage biopharmaceutical company focused on the
development of oral small molecule therapies for the treatment of
NASH, mucopolysaccharidoses (MPS) and other diseases with
significant unmet medical needs, today announced the half-year
report of its liquidity contract with Kepler Cheuvreux.
Under the liquidity contract granted to Kepler
Cheuvreux by Inventiva, the following resources were available in
the liquidity account as of December 31, 2021:
- Cash: € 761,542.29
- Number of shares: 45,462
- Number of executions on buy side on semester: 1,253
- Number of executions on sell side on semester: 1,425
- Traded volume on buy side on semester: 209,935 shares for €
2,438,368.87
- Traded volume on sell side on semester: 211,076 shares for €
2,510,782.11
At the last half-year report as of June 30,
2021, the following resources were available in the liquidity
account:
- Cash: € 689,129.05
- Number of shares: 46,603
- Number of executions on buy side on semester: 1,511
- Number of executions on sell side on semester: 1,435
- Traded volume on buy side on semester: 289,008 shares for €
3,547,633.77
- Traded volume on sell side on semester: 257,898 shares for €
3,208,144.47
When the contract was initially implemented, the
following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1,253 |
209,935 |
2,438,368.87 |
|
1,425 |
211,076 |
2,510,782.11 |
01/07/2021 |
- |
- |
- |
|
25 |
4,000 |
47,320.00 |
02/07/2021 |
- |
- |
- |
|
11 |
1,500 |
18,105.00 |
05/07/2021 |
6 |
2,500 |
29,750.00 |
|
- |
- |
- |
06/07/2021 |
- |
- |
- |
|
18 |
3,310 |
40,150.30 |
07/07/2021 |
15 |
4,500 |
53,370.00 |
|
18 |
3,474 |
41,965.92 |
08/07/2021 |
34 |
4,500 |
52,920.00 |
|
1 |
1 |
12.02 |
09/07/2021 |
7 |
672 |
7,788.48 |
|
1 |
1 |
11.76 |
12/07/2021 |
16 |
1,432 |
16,625.52 |
|
5 |
503 |
5,885.10 |
13/07/2021 |
4 |
896 |
10,304.00 |
|
11 |
1,229 |
14,305.56 |
14/07/2021 |
- |
- |
- |
|
8 |
886 |
10,410.50 |
15/07/2021 |
4 |
1,459 |
16,793.09 |
|
7 |
1,713 |
20,350.44 |
19/07/2021 |
2 |
500 |
5,930.00 |
|
2 |
168 |
2,009.28 |
20/07/2021 |
10 |
1,000 |
11,830.00 |
|
5 |
500 |
5,950.00 |
21/07/2021 |
- |
- |
- |
|
8 |
1,500 |
17,925.00 |
22/07/2021 |
1 |
1 |
12.00 |
|
27 |
2,527 |
30,728.32 |
23/07/2021 |
17 |
1,501 |
18,237.15 |
|
3 |
506 |
6,203.56 |
26/07/2021 |
47 |
4,499 |
53,358.14 |
|
- |
- |
- |
27/07/2021 |
11 |
1,156 |
13,432.72 |
|
13 |
1,280 |
15,065.60 |
28/07/2021 |
14 |
1,386 |
16,008.30 |
|
1 |
1 |
11.64 |
29/07/2021 |
18 |
2,265 |
25,843.65 |
|
4 |
1,669 |
19,410.47 |
30/07/2021 |
5 |
500 |
5,680.00 |
|
5 |
501 |
5,711.40 |
02/08/2021 |
4 |
1,000 |
11,380.00 |
|
8 |
1,225 |
14,099.75 |
03/08/2021 |
44 |
6,852 |
75,988.68 |
|
2 |
1,000 |
11,130.00 |
04/08/2021 |
32 |
4,500 |
48,870.00 |
|
- |
- |
- |
05/08/2021 |
54 |
7,000 |
72,310.00 |
|
- |
- |
- |
06/08/2021 |
26 |
6,000 |
58,620.00 |
|
- |
- |
- |
09/08/2021 |
16 |
2,500 |
23,750.00 |
|
- |
- |
- |
11/08/2021 |
9 |
1,500 |
14,340.00 |
|
- |
- |
- |
12/08/2021 |
16 |
1,300 |
12,233.00 |
|
- |
- |
- |
13/08/2021 |
3 |
500 |
4,585.00 |
|
- |
- |
- |
16/08/2021 |
- |
- |
- |
|
1 |
70 |
658.00 |
17/08/2021 |
- |
- |
- |
|
4 |
500 |
4,750.00 |
19/08/2021 |
- |
- |
- |
|
4 |
500 |
4,900.00 |
20/08/2021 |
9 |
1,300 |
12,402.00 |
|
- |
- |
- |
23/08/2021 |
- |
- |
- |
|
15 |
1,248 |
12,367.68 |
24/08/2021 |
- |
- |
- |
|
7 |
1,229 |
12,314.58 |
25/08/2021 |
- |
- |
- |
|
8 |
2,023 |
20,594.14 |
26/08/2021 |
- |
- |
- |
|
1 |
500 |
5,100.00 |
27/08/2021 |
7 |
500 |
5,050.00 |
|
17 |
2,592 |
26,723.52 |
30/08/2021 |
- |
- |
- |
|
13 |
1,908 |
20,110.32 |
31/08/2021 |
- |
- |
- |
|
30 |
4,600 |
50,232.00 |
01/09/2021 |
6 |
1,500 |
16,365.00 |
|
12 |
2,748 |
30,805.08 |
02/09/2021 |
29 |
1,000 |
11,080.00 |
|
11 |
2,752 |
31,042.56 |
03/09/2021 |
2 |
340 |
3,842.00 |
|
1 |
19 |
216.60 |
06/09/2021 |
1 |
160 |
1,808.00 |
|
6 |
981 |
11,212.83 |
07/09/2021 |
4 |
577 |
6,572.03 |
|
2 |
774 |
8,916.48 |
08/09/2021 |
3 |
244 |
2,781.60 |
|
9 |
1,000 |
11,530.00 |
09/09/2021 |
- |
- |
- |
|
26 |
3,551 |
41,866.29 |
10/09/2021 |
13 |
2,000 |
23,360.00 |
|
- |
- |
- |
13/09/2021 |
52 |
8,179 |
91,604.80 |
|
- |
- |
- |
14/09/2021 |
- |
- |
- |
|
15 |
1,500 |
16,875.00 |
15/09/2021 |
2 |
401 |
4,515.26 |
|
4 |
2,000 |
22,860.00 |
16/09/2021 |
- |
- |
- |
|
4 |
1,000 |
11,590.00 |
17/09/2021 |
- |
- |
- |
|
21 |
2,684 |
31,590.68 |
20/09/2021 |
5 |
1,500 |
17,625.00 |
|
23 |
3,316 |
39,360.92 |
21/09/2021 |
5 |
1,000 |
11,830.00 |
|
10 |
1,000 |
11,930.00 |
22/09/2021 |
- |
- |
- |
|
41 |
6,500 |
80,925.00 |
23/09/2021 |
4 |
1,500 |
18,465.00 |
|
9 |
1,000 |
12,480.00 |
24/09/2021 |
15 |
5,000 |
60,400.00 |
|
18 |
2,500 |
30,900.00 |
27/09/2021 |
17 |
2,001 |
24,072.03 |
|
22 |
3,001 |
36,462.15 |
28/09/2021 |
9 |
2,000 |
24,060.00 |
|
7 |
1,500 |
18,345.00 |
29/09/2021 |
15 |
3,001 |
35,471.82 |
|
5 |
373 |
4,423.78 |
30/09/2021 |
4 |
499 |
5,818.34 |
|
11 |
3,127 |
37,430.19 |
01/10/2021 |
26 |
4,805 |
55,930.20 |
|
7 |
820 |
9,635.00 |
04/10/2021 |
4 |
1,500 |
17,265.00 |
|
5 |
510 |
5,946.60 |
05/10/2021 |
5 |
695 |
7,950.80 |
|
13 |
1,000 |
11,580.00 |
06/10/2021 |
13 |
2,501 |
28,411.36 |
|
9 |
500 |
5,780.00 |
07/10/2021 |
17 |
3,399 |
37,796.88 |
|
4 |
1,000 |
11,180.00 |
08/10/2021 |
16 |
3,100 |
33,728.00 |
|
9 |
2,000 |
22,060.00 |
11/10/2021 |
1 |
1 |
10.80 |
|
42 |
4,000 |
44,320.00 |
12/10/2021 |
- |
- |
- |
|
52 |
6,576 |
75,689.76 |
13/10/2021 |
1 |
500 |
5,800.00 |
|
5 |
500 |
5,850.00 |
14/10/2021 |
6 |
1,500 |
17,415.00 |
|
2 |
500 |
5,880.00 |
15/10/2021 |
5 |
1,000 |
11,580.00 |
|
2 |
119 |
1,392.30 |
18/10/2021 |
10 |
2,000 |
22,920.00 |
|
9 |
500 |
5,800.00 |
19/10/2021 |
- |
- |
- |
|
42 |
6,475 |
77,635.25 |
20/10/2021 |
13 |
1,626 |
19,430.70 |
|
3 |
1,000 |
12,340.00 |
21/10/2021 |
1 |
500 |
6,010.00 |
|
17 |
2,500 |
30,650.00 |
22/10/2021 |
6 |
1,001 |
12,242.23 |
|
14 |
1,500 |
18,615.00 |
25/10/2021 |
14 |
3,429 |
41,765.22 |
|
13 |
2,771 |
34,138.72 |
26/10/2021 |
6 |
2,000 |
24,940.00 |
|
46 |
6,729 |
84,650.82 |
27/10/2021 |
27 |
5,001 |
62,512.50 |
|
5 |
1,174 |
14,921.54 |
28/10/2021 |
3 |
1,001 |
12,442.43 |
|
12 |
2,406 |
30,219.36 |
29/10/2021 |
1 |
498 |
6,155.28 |
|
22 |
3,920 |
49,901.60 |
01/11/2021 |
5 |
501 |
6,412.80 |
|
7 |
1,000 |
12,980.00 |
02/11/2021 |
4 |
1,000 |
12,780.00 |
|
3 |
1,500 |
19,425.00 |
03/11/2021 |
21 |
3,823 |
48,513.87 |
|
- |
- |
- |
04/11/2021 |
13 |
4,176 |
52,534.08 |
|
49 |
5,741 |
73,255.16 |
05/11/2021 |
26 |
5,570 |
68,789.50 |
|
- |
- |
- |
08/11/2021 |
7 |
1,891 |
22,559.63 |
|
- |
- |
- |
09/11/2021 |
5 |
1,483 |
17,499.40 |
|
56 |
6,222 |
76,095.06 |
10/11/2021 |
15 |
2,000 |
24,260.00 |
|
1 |
136 |
1,672.80 |
11/11/2021 |
25 |
4,600 |
57,224.00 |
|
53 |
4,957 |
62,160.78 |
12/11/2021 |
23 |
3,400 |
41,140.00 |
|
1 |
1 |
12.46 |
15/11/2021 |
19 |
2,500 |
29,650.00 |
|
3 |
1,000 |
11,880.00 |
16/11/2021 |
30 |
2,611 |
30,679.25 |
|
21 |
1,000 |
11,980.00 |
17/11/2021 |
9 |
1,489 |
17,227.73 |
|
2 |
500 |
5,850.00 |
18/11/2021 |
8 |
900 |
10,332.00 |
|
2 |
1,000 |
11,630.00 |
19/11/2021 |
30 |
2,774 |
31,817.78 |
|
8 |
2,613 |
30,336.93 |
22/11/2021 |
- |
- |
- |
|
15 |
2,946 |
34,409.28 |
23/11/2021 |
1 |
20 |
233.20 |
|
23 |
2,996 |
35,742.28 |
24/11/2021 |
17 |
3,519 |
40,996.35 |
|
14 |
1,506 |
17,680.44 |
25/11/2021 |
1 |
6 |
70.20 |
|
30 |
3,958 |
47,218.94 |
26/11/2021 |
12 |
2,995 |
35,191.25 |
|
11 |
2,000 |
23,660.00 |
29/11/2021 |
- |
- |
- |
|
21 |
2,643 |
31,478.13 |
30/11/2021 |
21 |
4,499 |
52,773.27 |
|
7 |
1,000 |
11,760.00 |
01/12/2021 |
- |
- |
- |
|
29 |
3,857 |
46,014.01 |
02/12/2021 |
9 |
1,938 |
23,081.58 |
|
3 |
1,183 |
14,172.34 |
03/12/2021 |
7 |
2,562 |
30,308.46 |
|
7 |
1,183 |
14,172.34 |
06/12/2021 |
- |
- |
- |
|
22 |
4,615 |
55,564.60 |
07/12/2021 |
3 |
500 |
6,030.00 |
|
13 |
2,000 |
24,480.00 |
08/12/2021 |
- |
- |
- |
|
23 |
3,500 |
43,890.00 |
09/12/2021 |
9 |
3,000 |
36,240.00 |
|
13 |
1,500 |
18,225.00 |
10/12/2021 |
11 |
2,500 |
30,000.00 |
|
2 |
501 |
6,092.16 |
13/12/2021 |
13 |
1,500 |
17,715.00 |
|
13 |
2,000 |
23,860.00 |
14/12/2021 |
- |
- |
- |
|
13 |
1,999 |
24,247.87 |
15/12/2021 |
16 |
2,000 |
24,040.00 |
|
- |
- |
- |
16/12/2021 |
8 |
2,000 |
24,240.00 |
|
19 |
3,033 |
36,941.94 |
17/12/2021 |
2 |
500 |
6,030.00 |
|
2 |
468 |
5,709.60 |
20/12/2021 |
30 |
3,501 |
41,486.85 |
|
- |
- |
- |
21/12/2021 |
5 |
1,499 |
17,403.39 |
|
7 |
1,099 |
12,847.31 |
22/12/2021 |
3 |
16 |
185.60 |
|
15 |
3,453 |
41,125.23 |
23/12/2021 |
10 |
1,484 |
17,644.76 |
|
7 |
2,454 |
29,619.78 |
24/12/2021 |
1 |
1 |
12.06 |
|
7 |
686 |
8,382.92 |
27/12/2021 |
12 |
2,999 |
36,437.85 |
|
15 |
1,807 |
22,298.38 |
28/12/2021 |
18 |
3,000 |
35,940.00 |
|
8 |
1,000 |
12,180.00 |
29/12/2021 |
8 |
2,000 |
23,620.00 |
|
5 |
1,518 |
18,140.10 |
30/12/2021 |
- |
- |
- |
|
2 |
11 |
130.90 |
31/12/2021 |
4 |
500 |
5,880.00 |
|
- |
- |
- |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of preclinical
programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. In 2020, Inventiva announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
both FDA Breakthrough Therapy and Fast Track designation for
lanifibranor in the treatment of NASH. Lanifibranor is currently
being evaluated in a pivotal Phase III clinical trial.
The Company has established a strategic
collaboration with AbbVie in the area of autoimmune diseases
resulting in the discovery of the drug candidate cedirogant
(AABV-157), an oral RORg inverse agonist. Cedirogant has reached
clinical proof of concept during a Phase Ib clinical trial and is
currently being evaluated in a Phase IIb clinical trial in patients
with moderate to severe chronic plaque psoriasis. This
collaboration enables Inventiva to receive payments upon the
achievement of pre-clinical, clinical, regulatory and commercial
milestones, in addition to royalties on any approved products
resulting from this collaboration.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients in 2019 and
received both FDA Fast Track and Rare Paediatric Disease
designation for odiparcil in MPS VI.In parallel, Inventiva is in
the process of selecting an oncology development candidate for its
Hippo signalling pathway program.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupLaurence Frost / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
Important Notice
This press release contains forward-looking
statements, forecasts and estimates with respect to Inventiva’s
clinical trials, clinical trial data releases, clinical development
plans, milestone and royalty payments and anticipated future
activities of Inventiva. Certain of these statements, forecasts and
estimates can be recognized by the use of words such as, without
limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and
similar expressions. Such statements are not historical facts but
rather are statements of future expectations and other
forward-looking statements that are based on management's beliefs.
These statements reflect such views and assumptions prevailing as
of the date of the statements and involve known and unknown risks
and uncertainties that could cause future results, performance or
future events to differ materially from those expressed or implied
in such statements. Actual events are difficult to predict and may
depend upon factors that are beyond Inventiva's control. There can
be no guarantees with respect to pipeline product candidates that
the clinical trial results will be available on their anticipated
timeline, with respect to the anticipated timeline for seeking of
regulatory approvals for candidates, or that candidates will
receive the necessary regulatory approvals. Actual results may turn
out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent
commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's
clinical trials may not support Inventiva's product candidate
claims, Inventiva may encounter substantial delays in its clinical
trials or Inventiva may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities, enrollment
and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic. Given
these risks and uncertainties, no representations are made as to
the accuracy or fairness of such forward-looking statements,
forecasts and estimates. Furthermore, forward-looking statements,
forecasts and estimates only speak as of the date of this press
release. Readers are cautioned not to place undue reliance on any
of these forward-looking statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2020 filed with the
Autorité des Marchés Financiers on March 15, 2021, the Annual
Report on Form 20-F for the year ended December 31, 2020 filed with
the Securities and Exchange Commission on March 15, 202, Amendment
No. 1 to our Annual Report on Form 20-F for the year ended December
31, 2020 filed with the Securities and Exchange Commission on March
24, 2021, as well as the full-year financial report for the year
ended December 31, 2020 for additional information in relation to
such factors, risks and uncertainties.
Except as required by law, Inventiva has no
intention and is under no obligation to update or review the
forward-looking statements referred to above. Consequently,
Inventiva accepts no liability for any consequences arising from
the use of any of the above statements.
- Inventiva - PR - Liquidity contract - H2 21 - EN - 14 01
2022
Inventiva (EU:IVA)
Historical Stock Chart
From May 2024 to Jun 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2023 to Jun 2024